Anti-epidemic Chinese medicines are frequently out of the market. Oncology drugs embark on the journey of clinical trials. Multi-pipeline product innovation has a bright future.

Recently, Buchang Pharmaceutical (603858, SH) announced that its holding subsidiary Zhejiang Tianyuan Biopharmaceutical Co., Ltd. has received the approval and issuance of the Zhejiang Provincial Food and Drug Administration for group A and group C meningococci. The re-registration approval notice for polysaccharide vaccine and ACYW135 meningococcal polysaccharide vaccine drugs marks another milestone in the company’s vaccine product layout.

In recent years, as a well-known domestic traditional Chinese medicine company, Buchang Pharmaceutical has continued to develop its cardiovascular and cerebrovascular proprietary Chinese medicines, and its anti-epidemic traditional Chinese medicine Xuanfeibaidu Granules have frequently left the industry and gone abroad; at the same time, the company has established a foothold in With the expansion of Chinese patent medicines into chemical drugs, biopharmaceuticals and other industries, two oncology drugs of the subsidiary have embarked on clinical trials in the first half of this year, and currently there are no similar target/dual-target drugs approved for marketing at home and abroad.

Buchang Pharmaceutical President Zhao Chao once said that Buchang Pharmaceutical insists on making scientific and modern traditional Chinese medicine. In recent years, the promulgation of industry-friendly documents such as the "14th Five-Year Plan for the Development of Traditional Chinese Medicine" and the "Notice on Several Policies and Measures to Accelerate the Development of Characteristics of Traditional Chinese Medicine" have clarified the importance of traditional Chinese medicine and innovation.

In the future, with the spring breeze of policies, the innovative results of Buchang Pharmaceutical's three-dimensional product layout are worthy of attention.

Anti-epidemic traditional Chinese medicines are frequently out of the market, and the company’s net profit in the first quarter increased by 5.91% year-on-year

As a traditional Chinese medicine company that started with cardiovascular and cerebrovascular proprietary Chinese medicines, Buchang Pharmaceutical has always been the leader in the industry , its founder, Professor Zhao Buchang, as an expert in the field of cardiovascular and cerebrovascular diseases, earlier put forward the slogan of simultaneous treatment of the brain and heart, which is the last word in efficacy, and has a high influence in the field of simultaneous brain and heart therapy and traditional Chinese medicine pharmaceuticals.

In 2021, the company's comprehensive market share of proprietary Chinese medicines ranks among the top in China (urban public, urban community, county-level public, township health) (Chinese patent medicines) (cardiocerebrovascular disease drugs). In addition, the company ranked second on the list of the top 100 Chinese traditional medicine companies in 2020.

Buchang Pharmaceutical has always been rooted in Heze, Shandong, where it was registered, and is a major local taxpayer. From 2018 to 2020, the tax paid in Heze, Shandong was 393.8192 million yuan, 211.5592 million yuan, and 273.5137 million yuan respectively. Since its establishment, The cumulative tax payment exceeds 14.5 billion yuan, and the cumulative tax payment and annual tax payment rank among the top three in Heze.

At present, Buchang Pharmaceutical’s products are still mainly concentrated in the field of cardiovascular and cerebrovascular drugs. In the past year, the company's five exclusive varieties, Naoxintong Capsules, Wenxin Granules, Danhong Injection, Guhong Injection, and Compound Qutide Injection, contributed significantly to the performance. Among them, the top four well-known exclusive varieties have a total sales revenue Reaching 7.397 billion yuan, accounting for 46.93% of total revenue in 2021.

In addition, the company's products also cover the treatment of major diseases such as gynecology, diabetes, malignant tumors, digestive system and respiratory system.

However, during the epidemic prevention and control period, the most famous thing for the company was the Xuanfei Baidu Granules that were emergency approved last year.

In December last year, Buchang Pharmaceutical announced a newly obtained invention patent certificate. The company’s two patents include an anti-coronavirus traditional Chinese medicine granule and its preparation method and use, and an anti-coronavirus traditional Chinese medicine. The composition and its use in treating inflammation have obtained an invention patent certificate issued by the State Intellectual Property Office.

In the first half of this year, Xuanfeibaidu Granules were listed as a general recommended drug during the clinical treatment period (confirmed cases) by the "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Ninth Edition)".

On April 11, Buchang Pharmaceutical donated more than 10,000 boxes of Xuanfei Baidu Granules to Shanghai Sixth People’s Hospital, echoing what Zhao Tao, chairman of Buchang Pharmaceutical, often expressed, that is, true Entrepreneurs must have a strong sense of social responsibility. We must be on the front line at critical moments, shoulder our social responsibilities, and give back to the society every step of the way.

This famous anti-epidemic traditional Chinese medicine also went abroad in the first half of the year.

According to the company’s announcement in May, Buchang Pharmaceutical’s Xuanfei Baidu Granules received the drug registration approval document approved and issued by the Ministry of Health of Uzbekistan. The company has the qualifications to market as a drug in the Uzbekistan market. Qualifications to sell this product.

Previously, Xuanfei Baidu Granules had been registered in Canada as a natural health product and obtained marketing approval.

As of May 10, the sales revenue of Xuanfeibaidu Granules has reached 22.937 million yuan; according to Buchang Pharmaceutical’s 2022 first quarter report, the company achieved a net profit attributable to the parent company of 430 million yuan from January to March. A year-on-year increase of 5.91%.

Oncology drugs have embarked on the journey of clinical trials, and multi-pipeline product innovation can be expected in the future

During the two sessions this year, Zhao Chao, deputy to the National People’s Congress and president of Buchang Pharmaceutical, said that Buchang Pharmaceutical will be in 30 During the years of development, we have always adhered to the core of patented Chinese patent medicines and been committed to the modernization of Chinese medicines. We have given full play to the important role of Chinese medicines in the field of cardiovascular and cerebrovascular diseases and chronic diseases, and formed a traditional Chinese medicine tradition based on the cardiovascular and cerebrovascular markets and covering the traditional Chinese medicines. A three-dimensional product layout focusing on advantageous areas, focusing on major disease species, and cultivating major varieties.

The annual report shows that as of December 2021, Buchang Pharmaceutical has 227 products under development, including 12 traditional Chinese medicines, 193 chemical drugs, 17 biological drugs, and 5 medical devices. This year, the company’s drug layout is still accelerating.

In terms of chemical drugs, in July, Desloratadine tablets from Shandong Danhong Pharmaceutical Co., Ltd., a subsidiary of Buchang Pharmaceutical, obtained the "Drug Registration Certificate" and can be used to relieve chronic idiopathic urticaria and Symptoms associated with allergic rhinitis.

In the seventh batch of national centralized procurement, Buchang Pharmaceutical’s subsidiaries Shaanxi Buchang and Qionglai Tianyin respectively won the bid for products, and related products lacosamide tablets and mycophenolate mofetil capsules were The procurement cycle is three years, laying the foundation for increasing market share and the company's brand influence.

In terms of vaccines, in April this year, the quadrivalent influenza virus split vaccine of Zhejiang Tianyuan, a subsidiary of Buchang Pharmaceuticals, was approved for collection of human genetic resources in China and officially launched Phase III clinical trials, which can be used to stimulate the body’s production Immunity against influenza viruses, preventing influenza caused by this strain.

In terms of oncology drugs, in April and July this year, Buchang Pharmaceutical successively announced the clinical trial of BC004 for injection by its holding subsidiary Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. (referred to as Luzhou Buchang) The application was approved, and the clinical trial application for BC008-1A injection was accepted by the State Food and Drug Administration.

The announcement shows that BC004 for injection is a recombinant anti-HER2/CD3 humanized bispecific antibody drug, mainly used to treat HER2-positive advanced solid tumors, including HER2-positive breast cancer and gastric cancer/gastroesophageal junction Adenocarcinoma, etc.; BC008-1A injection is a dual-antibody drug that specifically targets PD-1 and TIGIT. Its main indication is advanced solid tumors.

It is worth noting that for the above two drugs, there are currently no similar target/dual target drugs approved for marketing at home and abroad.

In the future, subsidiaries will still be an important starting point for Buchang Pharmaceutical to insist on developing scientific and technological traditional Chinese medicine, modern traditional Chinese medicine, and comprehensive health layout.

According to the 2021 annual report, Buchang Pharmaceutical invested in and established 6 companies during the reporting period and plans to invest in 5 companies. In the first half of this year, Buchang Pharmaceutical successively invested in and established several subsidiaries such as Beijing Buchang Health Consulting Co., Ltd. and Changsha Zhongchi Biotechnology Co., Ltd.

In March this year, the "14th Five-Year Plan for the Development of Traditional Chinese Medicine" was issued, clarifying measures to achieve high-quality development of traditional Chinese medicine in the new era. In the future, with the spring breeze of policies and the efforts of the subsidiary's R&D team, the innovative achievements of Buchang Pharmaceutical, a leading traditional Chinese medicine company, are still worthy of attention.

If you want to know more real-time financial news, please follow us.